Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | August 26, 2026 | August 27, 2026 |
| Evolus, Inc.EOLS · Entity 5341 | Director · See Remarks | September 02, 2026 | September 04, 2026 |
| Vyome Holdings, IncOBLN · Entity 1824 | Director | July 23, 2019 | July 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 40,625 |
Reported balance
After 2026-08-26 transaction · row 1
1 source rowRow 1 · 2026-08-26 · Purchase · Acquired 10,000 · Balance 40,625 F1: On August 26, 2026, the reporting person acquired 10,000 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 26, 2026, the reporting person acquired 10,000 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers.
Evolus, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 499,592 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 105,108 · Balance 499,592 F1: The shares were sold in multiple trades at prices ranging from $9.00 to $9.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in multiple trades at prices ranging from $9.00 to $9.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Vyome Holdings, Inc
Report date July 23, 2019 · Filed July 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Restricted Stock Units)SEC Table I · non-derivative | Direct | 83,619 |
Reported balance
After 2019-07-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 78,125 · Balance 83,619 F1: This award will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the annual meeting of the Issuer's stockholders immediately following the grant date. F2: Share amounts do not reflect the impact of a 1-for-10 reverse stock split that became effective after the grant date for the options referenced herein. |
Filing footnotes · ownership attribution and instrument terms
F1: This award will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the annual meeting of the Issuer's stockholders immediately following the grant date.
F2: Share amounts do not reflect the impact of a 1-for-10 reverse stock split that became effective after the grant date for the options referenced herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 23:04 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 105,108 | $9.04 | $950,018.66 |
DisclosureSEC source: 0001700836-26-000003 · wk-form4_1788563093.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,592 F1 · price: The shares were sold in multiple trades at prices ranging from $9.00 to $9.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 21:26 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001493152-26-040450 · ownership.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,625 F1 · shares: On August 26, 2026, the reporting person acquired 10,000 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 23:19 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 13,669 | $4.75 | $64,929.12 |
DisclosureSEC source: 0001570562-26-000049 · wk-form4_1774048737.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the settlement of restricted stock unit awards. F2 · price: The shares were sold in multiple trades at prices ranging from $4.7498 to $4.775. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 00:00 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 116,720 | $4.89 | $570,562.38 |
DisclosureSEC source: 0001570562-26-000046 · wk-form4_1773878432.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 618,369 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards. F3 · price: The shares were sold in multiple trades at prices ranging from $4.8874 to $5.015. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 00:00 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 67,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-26-000046 · wk-form4_1773878432.xml · derivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,488 Underlying: Common Stock · 67,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As previously reported, on February 7, 2024, the Reporting Person was granted 134,977 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 134,977 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 67,489 shares of the Issuer's common stock. The remaining 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures. F1 · derivative.exercise_date: As previously reported, on February 7, 2024, the Reporting Person was granted 134,977 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 134,977 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 67,489 shares of the Issuer's common stock. The remaining 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures. F1 · derivative.expiration_date: As previously reported, on February 7, 2024, the Reporting Person was granted 134,977 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 134,977 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 67,489 shares of the Issuer's common stock. The remaining 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures. Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 00:00 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionCommon Stock | 67,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-26-000046 · wk-form4_1773878432.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 735,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: As previously reported, on February 7, 2024, the Reporting Person was granted 134,977 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 134,977 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 67,489 shares of the Issuer's common stock. The remaining 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:57 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 457,541 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001570562-26-000023 · wk-form4_1771552645.xml · derivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457,541 Underlying: Common Stock · 457,541 shares Expires 2036-02-17 F4 · derivative.exercise_date: The shares subject to the option vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control). Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:57 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantPerformance Restricted Stock Units · Derivative | 626,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-26-000023 · wk-form4_1771552645.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 626,424 Underlying: Common Stock · 626,424 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents the right to receive, upon vesting, up to 200% of the target number of shares of common stock of the issuer. F3 · derivative.exercise_date: The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period. F3 · derivative.expiration_date: The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:57 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 313,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-26-000023 · wk-form4_1771552645.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,600 F1 · shares: Represents shares issuable upon settlement of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control). Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:42 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 10,539 | $7.15 | $75,361.23 |
DisclosureSEC source: 0001570562-25-000119 · wk-form4_1767051725.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 354,388 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 12, 2025 Filed Dec 31, 2025 22:10 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantCommon stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-029839 · ownership.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,625 F1 · shares: Award of restricted stock under the 2024 Stock Incentive Plan. The award of restricted stock will vest in full on the one-year anniversary of December 12, 2025, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 20:42 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 16,582 | $9.89 | $164,054.02 |
DisclosureSEC source: 0001570562-25-000089 · wk-form4_1750106519.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,927 F2 · price: The shares were sold in multiple trades at prices ranging from $9.82 to $10.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:42 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 111,323 | $10.05 | $1,119,141.25 |
DisclosureSEC source: 0001570562-25-000089 · wk-form4_1750106519.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,509 F1 · price: The shares were sold in multiple trades at prices ranging from $10.00 to $10.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2025 Filed May 14, 2025 23:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 15,787 | $9.87 | $155,756.12 |
DisclosureSEC source: 0001570562-25-000079 · wk-form4_1747265241.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,832 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units. Read SEC document |
| March 27, 2025 Filed Mar 28, 2025 22:59 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 6,251 | $12.40 | $77,512.40 |
DisclosureSEC source: 0001570562-25-000056 · wk-form4_1743202752.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 508,619 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 22:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 103,376 | $13.26 | $1,370,248.88 |
DisclosureSEC source: 0001570562-25-000051 · wk-form4_1742509619.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,870 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $13.1765 to $13.256. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 135,925 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001570562-25-000042 · wk-form4_1741733675.xml · derivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,925 Underlying: Common Stock · 135,925 shares Expires 2035-03-07 F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantPerformance Restricted Stock Units · Derivative | 190,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-25-000042 · wk-form4_1741733675.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,799 Underlying: Common Stock · 190,799 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 95,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-25-000042 · wk-form4_1741733675.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,246 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:28 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 10,502 | $10.85 | $113,966.65 |
DisclosureSEC source: 0001570562-24-000138 · wk-form4_1735252082.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,847 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 00:30 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantCommon stock | 85,000 | $0.31 | $26,350.00 |
DisclosureSEC source: 0001493152-24-050504 · ownership.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionStock Option (Right to Buy) · Derivative | 175,940 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · derivative · entry 7 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,079 Underlying: Common Stock · 175,940 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested in full over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 6, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 175,940 | $12.59 | $2,214,486.40 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · nonDerivative · entry 5 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,349 F3 · price: The shares were sold in multiple trades at prices ranging from $12.40 to $12.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionCommon Stock | 175,940 | $7.28 | $1,280,843.20 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · nonDerivative · entry 4 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 709,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionStock Option (Right to Buy) · Derivative | 155,278 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · derivative · entry 6 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,281 Underlying: Common Stock · 155,278 shares Expires 2032-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 155,278 | $12.92 | $2,006,455.73 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · nonDerivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,349 F2 · price: The shares were sold in multiple trades at prices ranging from $12.77 to $13.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | Exercise / conversionCommon Stock | 155,278 | $5.46 | $847,817.88 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 23:01 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 140,214 | $12.73 | $1,784,685.86 |
DisclosureSEC source: 0001570562-24-000095 · wk-form4_1717714876.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,349 F1 · price: The shares were sold in multiple trades at prices ranging from $12.70 to $12.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2024 Filed May 15, 2024 00:56 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 16,051 | $12.72 | $204,126.99 |
DisclosureSEC source: 0001570562-24-000086 · wk-form4_1715734563.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,563 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The shares were sold in multiple trades at prices ranging from $12.51 to $13.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 23:08 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 6,236 | $13.86 | $86,430.96 |
DisclosureSEC source: 0001570562-24-000057 · wk-form4_1711753678.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,614 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 22:08 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 96,566 | $13.92 | $1,344,604.30 |
DisclosureSEC source: 0001570562-24-000053 · wk-form4_1711058882.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,850 F1 · kind: The sales reported on this Form 4 were mandated by the Issuer pursuant to Restricted Stock Unit Agreements requiring the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction, and does not represent a discretionary trade by the reporting person. F2 · price: The shares were sold in multiple trades at prices ranging from $13.555 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 01:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 7,706 | $13.08 | $100,803.73 |
DisclosureSEC source: 0001570562-24-000031 · wk-form4_1708738069.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 792,416 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:27 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 61,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000031 · wk-form4_1708738069.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800,122 F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (20,401 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:35 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 181,460 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001570562-24-000016 · wk-form4_1707521743.xml · derivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,460 Underlying: Common Stock · 181,460 shares Expires 2034-02-07 F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:35 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantPerformance Restricted Stock Units · Derivative | 134,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000016 · wk-form4_1707521743.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,977 Underlying: Common Stock · 134,977 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:35 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 134,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000016 · wk-form4_1707521743.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 738,920 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 22:10 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 75,000 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001493152-23-044908 · ownership.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-12-13 F1 · shares: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2 · price: Not Applicable Read SEC document |
| December 08, 2023 Filed Dec 8, 2023 23:15 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 31,300 | $9.73 | $304,505.18 |
DisclosureSEC source: 0001570562-23-000117 · wk-form4_1702077349.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,944 F2 · price: The shares were sold in multiple trades at prices ranging from $9.61 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 23:15 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 51,348 | $10.09 | $517,890.79 |
DisclosureSEC source: 0001570562-23-000117 · wk-form4_1702077349.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,244 F1 · price: The shares were sold in multiple trades at prices ranging from $10.00 to $10.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:25 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 14,778 | $10.27 | $151,770.06 |
DisclosureSEC source: 0001570562-23-000098 · wk-form4_1692231895.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,592 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs. Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 00:25 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 91,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000098 · wk-form4_1692231895.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,370 F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. On August 14, 2023, the Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of May 9, 2023. One-third of the PSU (30,601 shares) was vested and delivered immediately upon certification of the goal achievement. The remaining two-thirds will vest annually on the anniversary of May 9, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 08, 2023 Filed May 9, 2023 22:21 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantRestricted Stock Units · Derivative | 560,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000072 · wf-form4_168367086260672.xml · derivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the EOLS common stock. F2 · derivative.exercise_date: 40% of the stock units are eligible to vest if the average EOLS common stock closing price over 20 consecutive trading days is $30 or more and an additional 60% of the stock units are eligible to vest if the average EOLS common stock closing price over 20 consecutive trading days is $50 or more, in each case not later than five years after the grant of the award. Any units eligible to vest based on stock price will vest, subject to continued service, over the four-year period after the grant date. F2 · derivative.expiration_date: 40% of the stock units are eligible to vest if the average EOLS common stock closing price over 20 consecutive trading days is $30 or more and an additional 60% of the stock units are eligible to vest if the average EOLS common stock closing price over 20 consecutive trading days is $50 or more, in each case not later than five years after the grant of the award. Any units eligible to vest based on stock price will vest, subject to continued service, over the four-year period after the grant date. Read SEC document |
| April 20, 2023 Filed Dec 11, 2023 22:23 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 32,000 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001493152-23-044442 · ownership.xml · derivative · entry 3 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-04-20 F2 · shares: Options granted to Mr. Moatazedi in April 2023 as part of his fiscal 2023 Board compensation package. Final issuance was subject to and conditioned upon the approval by stockholders of the 2023 Stock Incentive Plan, which occured on December 7, 2023. F4 · price: Not Applicable Read SEC document |
| April 20, 2023 Filed Dec 11, 2023 22:23 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 25,000 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001493152-23-044442 · ownership.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-04-20 F1 · shares: Options granted to Mr. Moatazedi in April 2023 as a new Board member. Final issuance of the options was subject to and conditioned upon the approval by stockholders of the 2023 Stock Incentive Plan, which occured on December 7, 2023. F4 · price: Not Applicable F3 · derivative.exercise_date: 25% vesting on 12/7/2023, 25% on 12/07/2024, 25% on 12/07/2025 and 25% on 12/07/2026 Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:11 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 6,110 | $8.47 | $51,751.70 |
DisclosureSEC source: 0001570562-23-000048 · wf-form4_168012427789453.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 609,567 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 23:02 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 64,211 | $8.47 | $543,796.54 |
DisclosureSEC source: 0001570562-23-000046 · wf-form4_167900771235838.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,677 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $8.25 to $8.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:24 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 257,009 | $0.00 Strike: $11.04 | $0.00 |
DisclosureSEC source: 0001570562-23-000011 · wf-form4_167486547956707.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,009 Underlying: Common Stock · 257,009 shares Expires 2033-01-25 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:24 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 187,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000011 · wf-form4_167486547956707.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,888 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 16, 2022 Filed May 19, 2022 00:21 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 55,321 | $13.64 | $754,307.37 |
DisclosureSEC source: 0001570562-22-000108 · wf-form4_165291968277127.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,961 F1 · price: The shares were sold in multiple trades at prices ranging from $13.49 to $13.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 23:02 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 6,104 | $11.62 | $70,928.48 |
DisclosureSEC source: 0001570562-22-000088 · wf-form4_164868132773826.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,282 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.